Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. develops clinical-stage, oncology-focused antibody therapeutics targeting angiogenesis, immune activation and tumor-driven immunosuppression. News about CMPX centers on its antibody pipeline, including tovecimig, a DLL4 x VEGF-A bispecific antibody studied with paclitaxel in biliary tract cancer, and earlier-stage programs such as CTX-8371, CTX-10726 and CTX-471.
Recurring updates cover clinical trial results, FDA-related regulatory designations and interactions, medical-meeting presentations, pipeline expansion, financial results, cash resources, leadership changes and equity inducement grants under Nasdaq rules.
Compass Therapeutics (Nasdaq: CMPX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Completed enrollment of 150 patients in COMPANION-002 Phase 2/3 trial of CTX-009 for biliary tract cancers (BTC)
- Approved Investigator Sponsored Trial of CTX-009 in first-line BTC setting
- Encouraging preliminary data from COMPANION-003 Phase 2 trial of CTX-009 in colorectal cancer
- Planning Phase 2 monotherapy trial of CTX-471 with newly identified biomarker
- Completed first dosing cohort in Phase 1 study of CTX-8371
Q2 2024 net loss was $13.1 million ($0.10 per share). Cash position of $146 million provides runway into Q1 2027.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer treatments, has announced its participation in the Wedbush PacGrow Healthcare Conference. The event is scheduled for Tuesday, August 13, 2024, at 11 AM ET in New York City.
This conference provides Compass Therapeutics with an opportunity to showcase its progress in developing innovative oncology therapies. As a company dedicated to creating proprietary antibody-based therapeutics for multiple human diseases, Compass's participation in this healthcare conference could offer valuable insights into its current projects and future plans in the biotechnology sector.
Compass Therapeutics (Nasdaq: CMPX) has announced two significant developments in its biliary tract cancer (BTC) program:
1. Completed enrollment of 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel alone in previously treated, unresectable advanced metastatic or recurrent BTC.
2. Approved an Investigator Sponsored Trial (IST) to study CTX-009 in the first-line setting for BTC patients at The University of Texas MD Anderson Cancer Center. This trial will add CTX-009 to the standard first-line regimen of gemcitabine, cisplatin, and durvalumab.
These developments mark significant progress in Compass Therapeutics' oncology-focused antibody-based therapeutics program, potentially expanding treatment options for BTC patients.
Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City on June 5-6, 2024.
The chat is scheduled for June 5 at 1:00-1:25 PM ET and will be webcast live. The presentation will be archived for 90 days on the company's events page.
Compass Therapeutics (Nasdaq: CMPX) has announced a leadership change effective May 28, 2024. Thomas Schuetz, M.D., Ph.D., has been appointed President and CEO, succeeding Vered Bisker-Leib, Ph.D., M.B.A., who stepped down but will continue as a Senior Consultant for 15 months. Dr. Schuetz, previously President of Research and Development and Vice Chair of the Board, expressed enthusiasm about his return to the CEO role and the progress of the company's clinical programs. The Board of Directors thanked Dr. Bisker-Leib for her contributions and wished her well in future endeavors.
Compass Therapeutics announced Phase 1 data for CTX-471, a novel CD137 agonist antibody, demonstrating anti-tumor activity in patients who progressed on PD-1 or PD-L1 inhibitors. The data will be presented at the ASCO Annual Meeting 2024. Five clinical responses were observed, including a complete response in a patient with small-cell lung cancer and partial responses in patients with melanoma and mesothelioma. CTX-471 was well tolerated, with the main dose-limiting toxicity being thrombocytopenia, which resolved. A low incidence of liver toxicity and mostly low-grade adverse events were reported. The study involved 19 patients in the dose escalation phase and 60 in the dose expansion phase.
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on oncology, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will take place in New York City on May 20, 2024, with a fireside chat scheduled for 11:30 AM ET. A webcast of the chat will be available live and archived for 90 days on the company's events page. Compass Therapeutics specializes in developing antibody-based therapeutics aimed at treating various human diseases.
Compass Therapeutics, Inc. (Nasdaq: CMPX) reported their first quarter 2024 financial results and provided a business update. They received FDA Fast Track Designation for CTX-009 for the treatment of biliary tract tumors. Enrollment is progressing well in their clinical trials. They ended the quarter with $156 million in cash and marketable securities, extending their cash runway into late 2026.
Summary not available.
Summary not available.